{"type":"trials","record":{"id":32020,"source_id":"clinicaltrials-gov","external_id":"NCT05291676","title":"Systems Investigation of Vaccine Responses in Aging and Frailty","brief_summary":"This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Yale University","enrollment":96,"countries":["United States"],"start_date":"2023-11-06","completion_date":"2027-04-01","last_update_date":"2025-06-12","source_url":"https://clinicaltrials.gov/study/NCT05291676","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:23.954312+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"21 Years","comparator":"21-30 standard dose Fluad; 21-30 high dose Fluzone","organization":"Yale University","interventions":["Fluzone","Fluad"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in production of IL-6 in monocytes to assess innate immune inflammatory response — Baseline and at Day 2, 7, and…","Change in Hemagglutination inhibition titer (HAI) in response to vaccination — Baseline and Day 28","Change in transcriptomic analyses of gene expression — At Baseline, Day 2, Day 7, Day 28 and Day 70","Change in proteomic analyses — At Baseline, Day 2, Day 7, Day 28 and Day 70","Number of participants with changes in innate immune function from PBMCs and PRP as assessed using flow cytometry — At…","Number of participants with changes in B and T cell function from PBMCs as assessed using flow cytometry — At Baseline,…"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · NONE","source_has_results":false},"controlled_terms":["Influenza","Fluzone","Fluad"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct05291676","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-11-06 to 2027-04-01","comparator":"21-30 standard dose Fluad; 21-30 high dose Fluzone","confidence":"structured-source","population":"ALL · 21 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.505Z","intervention":["Fluzone","Fluad"],"participants":96,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in production of IL-6 in monocytes to assess innate immune inflammatory response — Baseline and at Day 2, 7, and…","Change in Hemagglutination inhibition titer (HAI) in response to vaccination — Baseline and Day 28","Change in transcriptomic analyses of gene expression — At Baseline, Day 2, Day 7, Day 28 and Day 70","Change in proteomic analyses — At Baseline, Day 2, Day 7, Day 28 and Day 70","Number of participants with changes in innate immune function from PBMCs and PRP as assessed using flow cytometry — At…","Number of participants with changes in B and T cell function from PBMCs as assessed using flow cytometry — At Baseline,…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Title supplies longevity context: aging, frailty.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/32020","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}